CXCL12 and chronic myelogenous leukemia, BCR-ABL1 positive: Yet another study reported that deletion of CXCL12 in mesenchymal stromal cells resulted in CML LSC expansion and increased sensitivity to TKI treatment, whereas endothelial cell-specific CXCL12 deletion decreased LSC proliferation [58].